🇺🇸 NGR-hTNF in United States

15 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 15

Most-reported reactions

1. Anaemia — 2 reports (13.33%)
2. Febrile Neutropenia — 2 reports (13.33%)
3. Hepatotoxicity — 2 reports (13.33%)
4. Neutropenia — 2 reports (13.33%)
5. Thrombocytopenia — 2 reports (13.33%)
6. Bronchopulmonary Aspergillosis — 1 report (6.67%)
7. Cardiotoxicity — 1 report (6.67%)
8. Constipation — 1 report (6.67%)
9. Deep Vein Thrombosis — 1 report (6.67%)
10. Infection — 1 report (6.67%)

Source database →

Frequently asked questions

Is NGR-hTNF approved in United States?

NGR-hTNF does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for NGR-hTNF in United States?

AGC Biologics S.p.A. is the originator. The local marketing authorisation holder may differ — check the official source linked above.